Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026

Aligos Therapeutics (Nasdaq: ALGS) will report its fourth quarter 2025 financial results on Thursday, March 5, 2026 before the open of U.S. markets.

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) will report its fourth quarter 2025 financial results on Thursday, March 5, 2026 before the open of U.S. markets.

The company is a clinical-stage biotechnology firm focused on therapies for liver and viral diseases; timing and format details for the release were announced on Feb. 26, 2026.

Argus Feb 26 session

+8.07% close to close Open Argus

Details

News Market Reaction – ALGS

On Feb 26, the day this news came out, ALGS closed 8.07% above the previous close.

Data tracked by StockTitan Argus for the Feb 26 session.

Market Context

On Feb 26, the day this news came out, the stock closed 8.1% above the previous close. A strong posi...

Analysis

On Feb 26, the day this news came out, the stock closed 8.1% above the previous close. A strong positive reaction aligns with how ALGS has sometimes responded to milestones such as leadership appointments and prior clinical updates, which saw moves up to 15.51%. Investors would likely weigh this earnings-date news against existing fundamentals from the last 10-Q, including net loss and cash runway disclosures. Past alignment between news tone and price moves suggests enthusiasm can build but may remain sensitive to subsequent financing or clinical data updates.

Key Figures

Earnings period: Fourth quarter 2025 Earnings release date: March 5, 2026

Earnings period

Fourth quarter 2025

Period to be reported in upcoming release

Earnings release date

March 5, 2026

Scheduled before U.S. market open

Historical Context

5 past events · Latest: Feb 23

5 events

1. Feb 23

   Clinical data update

   24h Move

   +2.1%

   Positive CROI data for HBV programs and PK data for ALG-097558.

2. Jan 30

   Inducement grants

   24h Move

   -0.6%

   Equity inducement awards of 81,100 options to new employees.

3. Jan 21

   Phase 2 study update

   24h Move

   -0.1%

   B-SUPREME Phase 2 enrollment and interim analysis timeline update.

4. Jan 13

   Leadership appointment

   24h Move

   +6.1%

   Appointment of Chief Commercial Officer to build commercial capabilities.

5. Dec 12

   Inducement grants

   24h Move

   +15.5%

   Stock option awards totaling 14,100 shares under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2025 financial results on Thursday, March 5, 2026, before the open of the U.S. financial markets.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Aligos Therapeutics (ALGS) report Q4 2025 results?

Aligos will report Q4 2025 results on March 5, 2026, before U.S. markets open. According to Aligos, the company scheduled the release on Feb. 26, 2026 and will provide full financial details in that report.

What time will Aligos (ALGS) release its March 5, 2026 Q4 2025 report?

The company said the Q4 2025 results will be released before the open of U.S. markets on March 5, 2026. According to Aligos, investors should expect the announcement prior to regular market hours, with any webcast details to follow.

Will Aligos (ALGS) include clinical updates with the Q4 2025 financial release?

The announcement confirms only the timing of the Q4 2025 financial results on March 5, 2026, before markets open. According to Aligos, no additional details about clinical or operational disclosures were provided in this notice.

How can investors access Aligos (ALGS) Q4 2025 results on March 5, 2026?

Investors should check the company’s investor communications for the March 5, 2026 release, issued before market open. According to Aligos, the results will be published by the company and likely posted on its investor relations channels.

Why does Aligos Therapeutics (ALGS) announce the Q4 2025 release date in advance?

Advance scheduling notifies investors and the market of the March 5, 2026 release timing before U.S. markets open. According to Aligos, the company issued the Feb. 26, 2026 notice to allow investor planning and participation.